Sec Form 4 Filing - MAROON JOSEPH C MD @ MYLAN INC. - 2015-01-30

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
MAROON JOSEPH C MD
2. Issuer Name and Ticker or Trading Symbol
MYLAN INC. [ MYL]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
1000 MYLAN BLVD
3. Date of Earliest Transaction (MM/DD/YY)
01/30/2015
(Street)
CANONSBURG, PA15317
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/30/2015 M 10,000 ( 1 ) A $ 20.86 51,787 D
Common Stock 01/30/2015 M 10,000 ( 2 ) A $ 22 61,787 D
Common Stock 01/30/2015 M 9,089 ( 3 ) A $ 15.8 70,876 D
Common Stock 01/30/2015 S 37,279 D $ 53.7283 ( 4 ) 33,597 D
Common Stock 02/02/2015 M 911 ( 3 ) A $ 15.8 34,508 D
Common Stock 02/02/2015 M 19,994 ( 5 ) A $ 12.96 54,502 D
Common Stock 02/02/2015 M 14,286 ( 6 ) A $ 13.43 68,788 D
Common Stock 02/02/2015 M 10,272 ( 7 ) A $ 20.52 79,060 D
Common Stock 02/02/2015 S 58,263 D $ 52.8739 ( 8 ) 20,797 D
Common Stock 02/03/2015 M 1,354 ( 7 ) A $ 20.52 22,151 D
Common Stock 02/03/2015 M 10,864 ( 9 ) A $ 23.9 33,015 D
Common Stock 02/03/2015 M 13,158 ( 10 ) A $ 21 46,173 D
Common Stock 02/03/2015 M 6,623 ( 11 ) A $ 31.63 52,796 D
Common Stock 02/03/2015 S 41,009 D $ 53.0135 ( 12 ) 11,787 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 20.86 01/30/2015 M 10,000 ( 14 ) 11/28/2015 Common Stock 10,000 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 22 01/30/2015 M 10,000 ( 15 ) 07/28/2016 Common Stock 10,000 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 15.8 01/30/2015 M 9,089 ( 16 ) 07/27/2017 Common Stock 9,089 $ 0 911 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 15.8 02/02/2015 M 911 ( 16 ) 07/27/2017 Common Stock 911 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 12.96 02/02/2015 M 19,994 ( 17 ) 04/25/2018 Common Stock 19,994 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 13.43 02/02/2015 M 14,286 ( 18 ) 05/07/2019 Common Stock 14,286 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 20.52 02/02/2015 M 10,272 ( 19 ) 05/14/2020 Common Stock 10,272 $ 0 1,354 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 20.52 02/03/2015 M 1,354 ( 19 ) 05/14/2020 Common Stock 1,354 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 23.9 02/03/2015 M 10,864 ( 20 ) 05/06/2021 Common Stock 10,864 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 21 02/03/2015 M 13,158 ( 21 ) 05/04/2022 Common Stock 13,158 $ 0 0 D
Non-Employee Director Stock Option - Right to Buy ( 13 ) $ 31.63 02/03/2015 M 6,623 ( 22 ) 05/28/2023 Common Stock 6,623 $ 0 0 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
MAROON JOSEPH C MD
1000 MYLAN BLVD
CANONSBURG, PA15317
X
Signatures
/s/ Bradley L. Wideman, by power of attorney 02/03/2015
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Represents acquisition of Mylan common stock upon exercise of stock options granted on November 28, 2005.
( 2 )Represents acquisition of Mylan common stock upon exercise of stock options granted on July 28, 2006.
( 3 )Represents acquisition of Mylan common stock upon exercise of stock options granted on July 27, 2007.
( 4 )Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on January 30, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 403,595 shares in transactions ranging from $53.01 to $54.00 with a weighted average price of $53.5684 as well as 205,341 shares in transactions ranging from $54.005 to $54.25 with a weighted average price of $54.0425. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person. These sales of common stock were executed pursuant to 10b5-1 trading plans dated November 9, 2014.
( 5 )Represents acquisition of Mylan common stock upon exercise of stock options granted on April 25, 2008.
( 6 )Represents acquisition of Mylan common stock upon exercise of stock options granted on May 7, 2009.
( 7 )Represents acquisition of Mylan common stock upon exercise of stock options granted on May 14, 2010.
( 8 )Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 2, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 937,763 shares in transactions ranging from $52.23 to $53.22 with a weighted average price of $52.8646 as well as 13,957 shares in transactions ranging from $53.23 to $53.745 with a weighted average price of $53.5027. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person. These sales of common stock were executed pursuant to 10b5-1 trading plans dated November 9, 2014.
( 9 )Represents acquisition of Mylan common stock upon stock options granted on May 6, 2011.
( 10 )Represents acquisition of Mylan common stock upon stock options granted on May 4, 2012.
( 11 )Represents acquisition of Mylan common stock upon stock options granted on May 28, 2013.
( 12 )Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 3, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 520,475 shares in transactions ranging from $52.50 to $53.25 with a weighted average price of $52.8739 as well as 149,400 shares at $53.50 and 1 share at $54.50. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person. These sales of common stock were executed pursuant to 10b5-1 trading plans dated November 9, 2014.
( 13 )This option exercise was executed pursuant to a 10b5-1 trading plan dated November 9, 2014.
( 14 )These options vested in full on November 28, 2005.
( 15 )These options vested in full on July 28, 2006.
( 16 )These options vested in full on July 27, 2007.
( 17 )These options vested in full on April 25, 2009.
( 18 )These options vested in full on May 7, 2010.
( 19 )These options vested in full on May 14, 2011.
( 20 )These options vested in full on May 6, 2012.
( 21 )These options vested in full on May 4, 2013.
( 22 )These options vested in full on May 28, 2014.

Remarks:
As disclosed in the proxy statement filed by Mylan Inc. ("Mylan") on December 24, 2014 and the Form 8-K filed by Mylan on November 5, 2014, the filing person has exercised the stock options shown on this Form 4 to mitigate the effects of the excise tax under Section 4985 of the Internal Revenue Code of 1986, as amended, in connection with the proposed acquisition (the "Transaction") by a new public company organized in the Netherlands of both Mylan and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business and has sold the shares reported on this Form 4 to mitigate the tax and other costs imposed as a result of such exercises and the Transaction.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.